Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

Dimensional Fund Advisors LP boosted its stake in Regeneron Pharmaceuticals by 3% in Q4, totaling over $418 million in ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. | ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Biocon Biologics Ltd, announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept, ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. Over the next few ...